18-1-1989. Diazepam has been exempted from price control.

(f) No such reports have been received in this Ministry.

Sale of Formulations without Price Approval

148. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that his Ministry has set up a monitoring cell for checking the increase in prices and overcharging of prices on drugs;

(b) whether it is also a fact that Monitoring cell is not compiling any details;

(c) what are the instances of overcharging of prices which came to the notice of the monitoring cell after the announcement of DPCO, 1987;

(d) what are the names of the finished medicines the prices of which have gone up by more than 100% after the announcement of DPCO, 1987;

(e) whether it is a fact that the number of formulations are being sold without price approval; and

(f) if so, the details of instances came to the notice of his Ministry?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) Only the work relating to monitoring of prices of non-scheduled drugs and formulations is being handled by the monitoring cell.

(c) to (f) Information to the extent available will be collected and laid on the Table of the House as early as possible.

Appointment of the Chairman of the Telecom Commission

149. SHRI GURUDAS DAS GUPTA:

SHRI CHATURANAN MISHRA:

Will the Minister of COMMUNICATIONS be pleased to state :

(a) whether it is a fact that Government have changed the rules and Cabinet decision in the case of appointment of the Chairman of the newly created Telecom Commission; and

(b) if so, what are the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF COMMUNICATIONS (SHRI GIRDHAR GOMANGO): (a) No, Sir.

(b) Does not arise.

Production of Doxycycline and Erythromycin

150. SHRI BHAGATRAM MANHAR:

DR. G. VIJAYA MOHAN REDDY:

Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that an investment of over rupees Five crores was made by IDPL on the project of Doxycycline and Erythromycin;

(b) whether it is also a fact that the production of these drugs has not been stabilised and the assets have become dead assets;

(c) what steps have been taken to fix responsibility for setting up such a plant;

(d) the names of other companies licensed to produce these drugs;